Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study.
Malapelle U, Pepe F, Pisapia P, Sgariglia R, Nacchio M, Barberis M, Bilh M, Bubendorf L, Büttner R, Cabibi D, Castiglia M, De Andrea CE, de Biase D, Dumur CI, Fontanini G, Freire J, Gristina V, Hofman P, Ilie M, Lozano MD, Merkelbach-Bruse S, Pappesch R, Pelusi N, Roma G, Russo A, Savic S, Siemanowski J, Tallini G, Tischler V, Vander Borght S, Weynand B, Xu T, Troncone G. Malapelle U, et al. Among authors: pappesch r. J Clin Pathol. 2022 Jun;75(6):416-421. doi: 10.1136/jclinpath-2021-207450. Epub 2021 Mar 25. J Clin Pathol. 2022. PMID: 33766954
Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation.
Heydt C, Wölwer CB, Velazquez Camacho O, Wagener-Ryczek S, Pappesch R, Siemanowski J, Rehker J, Haller F, Agaimy A, Worm K, Herold T, Pfarr N, Weichert W, Kirchner T, Jung A, Kumbrink J, Goering W, Esposito I, Buettner R, Hillmer AM, Merkelbach-Bruse S. Heydt C, et al. Among authors: pappesch r. BMC Med Genomics. 2021 Feb 27;14(1):62. doi: 10.1186/s12920-021-00909-y. BMC Med Genomics. 2021. PMID: 33639937 Free PMC article.
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
Riedel R, Fassunke J, Tumbrink HL, Scheel AH, Heydt C, Hieggelke L, Scheffler M, Heimsoeth A, Nogova L, Michels S, Weber JP, Fischer RN, Eisert A, Westphal T, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Castiglione R, Pappesch R, Rehker J, Jürgens J, Stoelben E, Bunck A, Kobe C, Merkelbach-Bruse S, Sos ML, Büttner R, Wolf J. Riedel R, et al. Among authors: pappesch r. Eur J Cancer. 2023 Jan;179:124-135. doi: 10.1016/j.ejca.2022.11.010. Epub 2022 Nov 15. Eur J Cancer. 2023. PMID: 36521334
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
Riedel R, Fassunke J, Scheel AH, Scheffler M, Heydt C, Nogova L, Michels S, Fischer RN, Eisert A, Scharpenseel H, John F, Ruge L, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Pappesch R, Rehker J, Bunck A, Kobe C, Keil F, Merkelbach-Bruse S, Büttner R, Wolf J. Riedel R, et al. Among authors: pappesch r. J Thorac Oncol. 2024 Jan;19(1):160-165. doi: 10.1016/j.jtho.2023.06.020. Epub 2023 Jul 8. J Thorac Oncol. 2024. PMID: 37429463
17 results